BUZZ-Skye Bioscience rises after experimental weight-loss drug shows promise in mice

Reuters2025-04-15
BUZZ-Skye Bioscience rises after experimental weight-loss drug shows promise in mice

** Shares of drug developer Skye Bioscience SKYE.O rise 11.5% to $1.46 premarket

** Co says its drug candidate, nimacimab, showed 23.5% weight loss in mice, comparable to Eli Lilly's LLY.N popular drug, tirzepatide, sold as Zepbound, and Novo Nordisk's NOVOb.CO experimental drug, monlunabant

** SKYE also says nimacimab, when combined with tirzepatide, showed a greater than 30% weight loss

** Initial data from SKYE's mid-stage study in obesity is expected in late Q3/early Q4 2025

** Up to last close, stock had fallen 53.7% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment